分组1 - Innovex International reported quarterly earnings of $0.2 per share, missing the Zacks Consensus Estimate of $0.29 per share, and down from $0.47 per share a year ago [1][2] - The company posted revenues of $273.6 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 14%, compared to year-ago revenues of $250.69 million [3] - Innovex International has outperformed the market with a 16.5% increase in shares since the beginning of the year, compared to the S&P 500's gain of 0.9% [4] 分组2 - The current consensus EPS estimate for the coming quarter is $0.35 on $240 million in revenues, and for the current fiscal year, it is $1.58 on $1 billion in revenues [8] - The Zacks Industry Rank for Oil and Gas - Mechanical and Equipment is in the top 32% of over 250 Zacks industries, indicating a favorable outlook for the industry [9]

Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.6 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -5.26%. A quarter ago, it was expected that this company would post a loss of $0.35 per share when it actually produced a loss of $0.3, delivering a surprise of +14.29%.Over the last four quarters, the company ...

Group 1 - Trevi Therapeutics, Inc. (TRVI) shares have increased by 6.5% over the past four weeks, closing at $10.64, with a mean price target of $21.5 indicating a potential upside of 102.1% [1] - The mean estimate consists of 12 short-term price targets with a standard deviation of $3.26, where the lowest estimate is $16.00 (50.4% increase) and the highest is $27.00 (153.8% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements, as indicated by a 0.7% increase in the Zacks Consensus Estimate for the current year [11][12] Group 2 - TRVI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential upside [13] - While consensus price targets are often viewed as important, they should be approached with skepticism due to historical inaccuracies in predicting actual stock price movements [3][10] - A low standard deviation among price targets indicates a high degree of agreement among analysts regarding the stock's price direction, which can serve as a starting point for further research [9]

Core Viewpoint - NN Inc. (NNBR) has received an upgrade to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][2]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with near-term stock price movements, particularly influenced by institutional investors [3]. - An increase in earnings estimates typically leads to higher fair value calculations for stocks, prompting institutional investors to buy or sell, thus affecting stock prices [3]. Company Performance and Outlook - The upgrade for NN indicates an improvement in the company's underlying business, which is expected to positively influence its stock price [4]. - Over the past three months, the Zacks Consensus Estimate for NN has increased by 21.7%, reflecting analysts' growing confidence in the company's earnings potential [7]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [6]. - The upgrade of NN to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [9].

Core Insights - Forum Energy Technologies (FET) reported quarterly earnings of $0.41 per share, exceeding the Zacks Consensus Estimate of $0.36 per share, and a significant improvement from a loss of $0.48 per share a year ago [1] - The earnings surprise of +13.89% indicates strong performance, with the company having surpassed consensus EPS estimates two times over the last four quarters [2] Financial Performance - The company posted revenues of $202.2 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 6.14%, and showing a slight increase from $201 million in the same quarter last year [3] - Forum Energy has topped consensus revenue estimates three times over the last four quarters [3] Stock Performance - Forum Energy shares have increased approximately 41% since the beginning of the year, significantly outperforming the S&P 500's gain of 0.5% [4] - The stock currently holds a Zacks Rank 1 (Strong Buy), indicating expectations for continued outperformance in the near future [7] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.32 on revenues of $193.8 million, and for the current fiscal year, it is $1.65 on revenues of $802.9 million [8] - The outlook for the industry, specifically the Oil and Gas - Mechanical and Equipment sector, is currently in the bottom 41% of Zacks industries, which may impact stock performance [9]

AMN Healthcare Services (AMN) came out with quarterly earnings of $0.22 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.75 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -1.12%. A quarter ago, it was expected that this health care staffing company would post earnings of $0.19 per share when it actually produced earnings of $0.39, delivering a surprise of +105.26%.Over the last four quart ...

分组1 - LegalZoom reported quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.18 per share, and down from $0.19 per share a year ago, representing an earnings surprise of -7.61% [1] - The company posted revenues of $190.27 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 3.22%, compared to year-ago revenues of $161.71 million [2] - LegalZoom shares have declined approximately 29.8% since the beginning of the year, while the S&P 500 has gained 0.5% [3] 分组2 - The current consensus EPS estimate for the coming quarter is $0.16 on revenues of $201.35 million, and for the current fiscal year, it is $0.74 on revenues of $802.25 million [7] - The Zacks Industry Rank indicates that the Industrial Services sector is currently in the bottom 32% of over 250 Zacks industries, suggesting that the outlook for the industry can significantly impact stock performance [8]

Core Viewpoint - Aldeyra Therapeutics, Inc. (ALDX) shows potential for significant upside, with a mean price target of $9 indicating a 79.3% increase from the current price of $5.02 [1] Price Targets and Analyst Estimates - The mean estimate consists of five short-term price targets with a standard deviation of $1.22, suggesting variability in analyst predictions [2] - The lowest price target of $7.00 indicates a 39.4% increase, while the highest target of $10.00 suggests a 99.2% increase [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Agreement - Analysts have shown increasing optimism about ALDX's earnings prospects, as evidenced by a positive trend in earnings estimate revisions [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 19.4%, with one estimate moving higher and no negative revisions [12] - ALDX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on consensus price targets for investment decisions may not be wise, as analysts' ability to set accurate targets has been questioned [3][7] - Price targets should be treated with skepticism, as they can often mislead investors [10]

分组1 - Verisk Analytics reported quarterly earnings of $1.82 per share, exceeding the Zacks Consensus Estimate of $1.6 per share, and showing an increase from $1.61 per share a year ago, resulting in an earnings surprise of +13.75% [1] - The company achieved revenues of $778.8 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.96%, and up from $735.6 million in the previous year [2] - Over the last four quarters, Verisk has consistently surpassed consensus EPS estimates four times and topped revenue estimates three times [2] 分组2 - The stock has underperformed, losing about 20.7% since the beginning of the year, while the S&P 500 has shown a zero return [3] - The company's earnings outlook is crucial for investors, with current consensus EPS estimates at $1.86 for the coming quarter and $7.70 for the current fiscal year [7] - The Zacks Industry Rank indicates that the Business - Information Services sector is in the bottom 37% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]

Core Viewpoint - Charles River Laboratories (CRL) reported quarterly earnings of $2.39 per share, exceeding the Zacks Consensus Estimate of $2.33 per share, but down from $2.66 per share a year ago [1] Financial Performance - The earnings surprise for the quarter was +2.51%, with the company having surpassed consensus EPS estimates in all four of the last quarters [2] - Revenues for the quarter were $994.23 million, surpassing the Zacks Consensus Estimate by 0.84%, compared to $1 billion in revenues a year ago [3] Stock Performance - Charles River shares have declined approximately 20.5% since the beginning of the year, contrasting with the S&P 500's zero return [4] Future Outlook - The company's earnings outlook is crucial for investors, with current consensus EPS estimates at $2.52 for the coming quarter and $10.59 for the current fiscal year, alongside revenues of $992.69 million and $4.07 billion respectively [5][8] - The Zacks Rank for Charles River is currently 3 (Hold), indicating expected performance in line with the market in the near future [7] Industry Context - The Medical Services industry, to which Charles River belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, suggesting potential challenges ahead [9]